Journal of Clinical Oncology
Articles in this Issue
Chronotherapy in metastatic melanoma: Retrospective outcomes of immunotherapy administration timing in a community practice.
e21580 Background: Circadian rhythms influence immune cell trafficking and PD-1/PD-L1 signaling, suggesting a potential re...
Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2).
TPS7099 Background: Inhibition of B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) has emerged as an effective fi...
Aspiration pneumonitis and inpatient outcomes in adult cancer hospitalizations: A 2018–2022 National Inpatient Sample analysis.
e23217 Background: Aspiration pneumonitis is frequently conflated with infectious pneumonia in hospitalized oncology popul...
Universal adipogenic and immunologic remodeling in the recurrent myeloid leukemia microenvironment of recurrent versus primary myeloid leukemias: An age-stratified analysis.
6596 Background: Disease recurrence is the primary cause of mortality in myeloid leukemias. While molecular studies sugges...
Multi-organ immune-related adverse events following immune checkpoint inhibitor therapy in patients with metabolic dysfunction–associated steatotic liver disease.
e24203 Background: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). Metaboli...
Targetable genomic alterations in early-onset colorectal cancer and their therapeutic implications: Real-world data.
e15542 Background: Colorectal cancer (CRC) diagnosed before the age of 50, referred to early-onset colorectal cancer (EOCR...
Survival outcomes of PD1/PDL1 inhibitor-based regimens in unresectable stage IIIB, IIIC, and IV non-small cell lung cancer.
e20569 Background: The five-year survival for patients with unresectable Stage IIIB and IIIC non–small cell lung cancer (N...
cfDNA sequencing as a cutting-edge technology to identify pathogenic germline variants from 8353 patients with advanced tumors at the Gustave Roussy Institute.
3061 Background: Large cfDNA panels used for somatic profiling can incidentally reveal pathogenic variants of potential ge...
Chemo-immunotherapy as a reshaper of immunosuppressive activity and gene expression of circulating monocytes in advanced non–small cell lung cancer.
e14538 Background: Circulating monocytes (CM) may acquire immunosuppressive activity (IA) and contribute to resistance to...
First-in-human phase 1 dose escalation and expansion study of PIN-5018, a CK1α-selective molecular glue degrader, in patients with advanced solid tumors.
TPS3168 Background: Casein kinase 1 alpha (CK1α) is a serine/threonine kinase involved in multiple oncogenic signaling pat...
Trends and disparities in hypertension mortality among patients with lung cancer: A retrospective CDC-WONDER analysis (1999-2020).
e20159 Background: Lung cancer (LC) is the leading cause of cancer deaths in the U.S., with older adults disproportionatel...
Spatial distribution and functional heterogeneity of CD56bright and CD56dim natural killer cells and the effects on the immune microenvironment in ovarian cancer.
5593 Background: Natural killer (NK) cells are key components of antitumor immunity, yet their functional heterogeneity an...
Proteogenomic profiling of gallbladder cancer for identification of distinct biology and subtype-specific therapeutic vulnerabilities.
e16263 Background: Gallbladder cancer (GBC) is an aggressive malignancy accounting for 80-95% of biliary tract cancers, wi...
Colorectal cancer with hypertension among middle aged and older adults in United States, 1999-2023.
e15683 Background: Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality globally. Hypertensi...
Plasma-TMB (pTMB) and circulating tumor fraction (ctF) dynamics as biomarkers of benefit from the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer (mCRC): A translational analysis of the AtezoTRIBE study.
2575 Background: TMB-high pMMR mCRC patients (pts) do not seem to derive benefit from immune checkpoint inhibitors (ICIs)....
Detection of adaptive immune receptor CDR3s in tumor proteomes and correlations with survival probabilities.
e12597 Background: T cell receptors (TCRs) and immunoglobulins (IGs) play an important role in cancer. Specifically, the c...
Expanding access to tyrosine kinase inhibitors for treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia in low- and middle-income countries.
1600 Background: Acute lymphoblastic leukemia (ALL) is a hematological malignancy affecting 300,000 people worldwide, with...
Next-generation multi-cancer early detection (MCED) assay: Independent blinded validation of a locked serum multi-omics NMR test with stage I sensitivity.
10536 Background: Blood-based MCED assays could complement existing screening, but many approaches show reduced sensitivit...
Validation of a tissue-based predictive RNA test for immunotherapy benefit in NSCLC: The PREDAPT study.
e14593 Background: Lung cancer remains the leading cause of cancer mortality worldwide. Immune checkpoint inhibitors targe...
Longitudinal assessment of interfractional geometrical variations of gastrointestinal organs in patients undergoing abdominal radiotherapy.
e16457 Background: Significant anatomical variations of organs-at-risk (OARs), particularly the stomach and duodenum, pose...
Disproportionate reporting of hepatic injury with acute leukemia therapies.
e18509 Background: Therapies to treat relapsed/refractory acute leukemia are associated with hepatotoxicity. Cholestatic a...
Impact of dual inhibition of iNOS and COX2 on antitumor immunity and response to immune checkpoint blockade in hepatocellular carcinoma.
3153 Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. Although im...
Real-world outcomes of dual checkpoint blockade versus PD-1/VEGF inhibitor combination as first-line therapy in metastatic renal cell carcinoma.
e16550 Background: Immune-based combinations have upstaged traditional treatment regimens by becoming the first-line thera...
Downstream mTOR effectors and VEGFR as biomarkers of malignant stratification in pathologic and genomic heterogeneity of PEComas.
e23527 Background: Perivascular epithelioid cell tumours (PEComas) are rare mesenchymal neoplasms characterized by co-expr...
Safety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML).
6507 Background: The gamma isoform of PI3K (PI3Kγ) directs a myeloid-specific signaling node (PI3Kγ-AKT1-PAK1) identified...